SML0042
Lazabemide hydrate
≥97% (HPLC)
别名:
N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H10ClN3O · xH2O
化学文摘社编号:
分子量:
199.64 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2
SMILES string
O.NCCNC(=O)c1ccc(Cl)cn1
InChI key
JYWYNPKXSLPWGV-UHFFFAOYSA-N
assay
≥97% (HPLC)
form
powder
storage condition
desiccated
color
white to tan
solubility
DMSO: ≥22 mg/mL
originator
Roche
storage temp.
room temp
Quality Level
Application
Lazabemide hydrate may be used in cell signaling studies.
Biochem/physiol Actions
Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Lazabemide is effective in treatment of Alzheimer′s disease and in combination with nicotine replacement therapy aids in smoking cessation.
Selective MAO-B inhibitor; Antiparkinson
Features and Benefits
This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
A M Cesura et al.
Advances in neurology, 80, 521-528 (1999-07-20)
R Raddatz et al.
The Journal of pharmacology and experimental therapeutics, 292(3), 1135-1145 (2000-02-25)
A series of phenoxy-substituted methylimidazoline derivatives were synthesized and used to define the ligand recognition properties of the imidazoline-binding domain (IBD) on monoamine oxidase (MAO)-B and its role in substrate processing. The rank order of potency for selected compounds in
Clinical trials of neuroprotection for Parkinson's disease.
Peter A LeWitt
Neurology, 63(7 Suppl 2), S23-S31 (2004-10-13)
Andrzej Dekundy et al.
Journal of neural transmission (Vienna, Austria : 1996), 118(12), 1703-1716 (2010-12-17)
Subtype 5 metabotropic glutamate receptors (mGluR5) are abundant in the basal ganglia, amygdala, septum, hippocampus, peripheral sensory neurones and dorsal horn of the spinal cord. Thus, mGluR5 has been implicated in central processes underlying movement control, emotion, learning, and nociception.
Glaucia H Braun et al.
Journal of biomolecular structure & dynamics, 25(4), 347-355 (2007-12-21)
Monoamine oxidase is a flavoenzyme bound to the mitochondrial outer membranes of the cells, which is responsible for the oxidative deamination of neurotransmitter and dietary amines. It has two distinct isozymic forms, designated MAO-A and MAO-B, each displaying different substrate
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持